Sarepta Therapeutics Inc said on
Monday the U.S. Food and Drug Administration declined to approve
its newest treatment for Duchenne muscular dystrophy (DMD),
citing safety concerns including the risk of infection and
The post UPDATE 2-U.S. FDA declines to approve Sarepta’s second Duchenne treatment appeared first on Wolfe’s Blog.